ArticleiScience2025
KLF13-mediated CES2 upregulation via p300-dependent acetylation sensitizes gastric cancer cells to irinotecan.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irinotecan (CPT-11) is a key chemotherapeutic agent for gastric cancer (GC), but its efficacy is limited by variable patient responses. The activation of CPT-11 to its active form, SN-38, depends on the enzyme carboxylesterase 2 (CES2), yet the regulation of CES2 in GC is poorly understood. Here, we identify Krüppel-like factor 13 (KLF13) as a direct transcriptional activator of CES2. We show that KLF13 expression correlates with CES2 levels and treatment response in GC patients. Mechanistically, KLF13 binds to specific elements in the CES2 promoter to drive its expression. This function of KLF13 is critically dependent on its acetylation by the co-activator p300, as demonstrated by site-directed mutagenesis and p300 inhibition. Functionally, the KLF13-CES2 axis dictates cellular sensitivity to CPT-11. Our findings unveil a p300-KLF13-CES2 signaling pathway that governs irinotecan sensitivity, providing potential predictive biomarkers and therapeutic targets for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.